Shelley Wood

We Recommend Predicted PPM picked up fewer “severe” cases than did measured PPM, providing some validation for VARC-3 recommendations.

A study tracking CV risks with a low-cal sweetener topped a diverse list of stories spanning meeting updates and sex advice.

This long-awaited RCT, seen by some as a COAPT/MITRA-FR tiebreaker, will be unveiled at ESC 2024—with key design tweaks.

A packed program leaves little time for warm beer or Buckingham Palace as the London edition of CVD's biggest congress kicks off.

A flurry of papers, including a meta-analysis of the three RCTs, reflect big interest and even larger, unanswered questions.

Critics were quick to point out that this small, short-term trial—mostly in patients with preserved EF—had no medical arm.

Most of our top stories this month stemmed from the ESC Congress—a mix of drug and device trials as well as guidelines.

This transcript has been edited for clarity. Robert A. Harrington, MD: Hi. I'm Bob Harrington, from Weill Cornell Medicine in New York City.

The 2024 conference has 28 late-breakers plus plenty of basic and population science. More than anything, it's a celebration.

A mixed bag of counterintuitive results hinders trial interpretation, but experts still see actionable results.